Emergence client, Delivra, announces partnership in the medical cannabis research, development and commercialization markets

Burlington, Ontario-and Charlottetown, PEI-based Emergence client, Delivra, has announced  a strategic partnership with Dosecann Inc. and ARA-Avanti Rx Analytics Inc. to develop a unique suite of standardized products for the medical cannabis research, development, and commercialization markets.


Dr. Joe Gabriel, CEO, Delivra

“The Federal Government of Canada has numerous concerns, and barriers to overcome, before legalizing cannabis, including stricter regulatory controls. The partnership between the three companies addresses many of these concerns, providing greater safety and efficacy of medical cannabis specific products for the patient, with products that provide consistent, accurate dosing, and that are manufactured under pharmaceutical GMP Standards,” Dr. Joseph Gabriele, Delivra’s Chief Executive Officer, told us.

The collaboration between Delivra, Dosecann and Avanti addresses an exploding field of medicine by seeking to standardize, validate, package and distribute cannabis products in innovative mono-dose delivery platforms to licensed producers and other future legal distribution networks.

delivra1According to Gabriele: “This agreement both validates Delivra’s proprietary transdermal platform technology and allows Delivra to capitalize on an unmet need in the pain market: to provide quality, accuracy, consistency and repeatable dosing using cannabis-based therapeutics.”

“This three-way joint venture with Delivra and Avanti enables us to potentially formulate, manufacture and distribute medical cannabis products that are standardized, quality controlled and provided through unique delivery platforms effectively dosing medical cannabis,” said Greg Boone, Founder of Dosecann.

For further information about this partnership, click here!

See also:  Emergence client, Delivra Corp’s LivRelief products to be distributed across Canada in single dose size and Emergence client, Delivra, set for US product launch


Delivra Corp. is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com.


ARA-Avanti Rx Analytics Inc. is the first Health Canada GMP and OCDS approved Contract Organization specializing in the field of controlled drugs and substances particularly in the area of Medicinal Marijuana, HEMP, Cannabinoids, and Marijuana based concentrated products.


Dosecann is a private specialty pharma company that has built a team of seasoned scientists, doctors and business leaders. We offer unique solutions to the emerging cannabis industry for numerous medical conditions.

Posted in Clients, News

Emergence Partner, Grant Thornton, outlines “Budget 2017” highlights

Federal Minister of Finance, Bill Morneau, presented his budget on March 22, 2017.

screen-shot-2017-01-23-at-1-21-28-pmAccording to Emergence Partner, Grant Thornton, who has shared their budget analysis with the Emergence community, the government is continuing with its planned focus on building a strong middle class through innovation, skills, partnership and fairness.

Budget 2017 focuses on giving talented people the skills they need to drive our most successful industries and high-growth companies forward, while investing in Canadians’ well-being through a focus on mental health, home care and indigenous health care.

Click here to view a summary of the tax measures that were announced and how they may impact you and your business.

The government will initiate three new expenditure management initiatives:

  • A comprehensive review of at least three federal departments (to be determined), with the aim to eliminate poorly targeted and inefficient programs, wasteful spending and inefficient programs, and ineffective and obsolete government initiatives.
  • Initiate a three-year review of federal fixed assets to identify ways to enhance or generate greater value from government assets.
  • Initiate a review of all federal innovation and clean technology programs across all departments, as federal programs are dispersed to simplify programming and better align resources to improve the effectiveness of innovation programs.

Please feel free to contact your local Grant Thornton office to discuss any questions you have regarding any of the proposed measures.

Posted in News, Partner

Emergence client, AIM OA, featured in March 2017 “Veterinary Practice” magazine

Professor Stuart Carmichael, co-founder of Emergence client, AIM OA Sys writes for this month’s Veterinary Practice magazine, arguing that surgery should not be regarded as the main option in the management of osteoarthritis (OA) joints, rather as one of the key tools available among many others for a good outcome.

Click here to read Stuart’s article on page 24.

Posted in Clients, News

Emergence client, AIM OA: defining the future of Canine Arthritis care

Emergence client, Aim.OA has developed a new, cloud-based electronic decision making tool for managing canine arthritis.

logo-blackThis new revolutionary system enables veterinary practices to create effective, individualized multimodal plans for each patient.

The new digitised process is based on the Aim-OA system, which has been developed and used in arthritis management for over 15 years by some of the world’s leading authorities in canine arthritis. The system also records interventions and monitors outputs.

The AIM OA System offers the veterinary profession a revolutionary new tool for successfully reducing pain and managing osteoarthritis (OA).

Designed to provide practices and pet owners with one common system for osteoarthritis management, the system uses a multi-modal approach, focusing on six key areas of the management of arthritis:

  • A – Analgesia,
  • B – Body Condition Score and diet,
  • C – Care with environmental and drug toxicity issues,
  • D – Disease modifications,
  • E – Exercise,
  • F – Follow up.

Aim.OA is a new, state of the art electronic decision making tool for managing arthritis. The system has been designed to provide practices with one common system for OA management, increasing efficiency and improving extended care for OA patients. Stuart Carmichael, Co-Founder

AIM OA is delivered via a cloud based app, enabling pet owners and vets to work together to build a totally bespoke plan for each individual patient to offer the best possible conditions for ongoing care.

Aim OA has been developed by two of the world’s leading veterinary clinicians in the canine orthopaedic and rehabilitation disciplines, Professor Stuart Carmichael an RCVS specialist in orthopaedics and a recognised authority on osteoarthritis and Dr David Prydie, one of the world’s leading canine rehabilitation practitioners.

The system is web based and consists of a series of questions for the pet owner that can be completed in the waiting room on an iPad or on a web enabled device, and a series of questions for the vet, based on their clinical examination of the patient.

The system then uses an algorithm to generate suggestions for each of the six areas for management, creating a traffic light system plan highlighting areas for focus which can be printed off and given to the owner along with the recommended exercises. Science and technology working in perfect harmony.

Using the broad knowledge and experience of world OA experts, AIM OA has been designed to be easy to use and apply in every day practice and to engage and involve the pet owner in their pet’s long term treatment plan – one of the most critical aspects of successful pain management and on going treatment for OA.

The system is evidence based, monitoring and evaluating the patient over time with the flexibility to adapt to the specific needs of that patient over time. Having one integrated system is hugely beneficial in terms of the resources of both the practice and the client and ultimately delivers effective management for this chronic condition whilst bonding clients to their veterinary practice.

Follow AIM OA on Twitter: @aim_oa


Posted in Clients, News

Natural Products Canada makes first investment in a Canadian natural product company

Our friends at Natural Products Canada (NPC) have announced their first investment in a Canadian natural product company. The NPC investment is in Canadian start-up, FireRein Inc.

Natural Products Canada is a Prince Edward Island based member of the network of Centres of Excellence for Commercialization and Research (CECR).

FireFireRein is a Napanee, Ontario-based company dedicated to providing the firefighting community with effective, innovative and sustainable technology solutions. The company is underpinned by an experienced team that includes firefighters from various backgrounds in urban, rural, industrial and wildland firefighting.

In response to the demands of today’s firefighting professionals, the company has created Eco-Gel™, the world’s first and only 100% bio-sourced and 100% food-grade water additive that when introduced into fire hose water streams creates a potent firefighting gel that “sticks and stays” on any surface and in any orientation.

Eco-Gel is an effective and non-toxic water additive that can “knock down” fires up to 55% faster while using up to 60% less water. Made from bio-renewable, food-grade ingredients, Eco-Gel™ is safe for the firefighter and the environment. The product was developed by a team of firefighters, scientists and business professionals, and early proof-of-concept work was done in collaboration with GreenCentre Canada.

“We are thrilled to contribute to the acceleration of a company that is adding such an important natural product to the market,” Shelley King, CEO of Natural Products Canada told us. “FireRein is a great example of the commercialization potential in Canada’s research and innovation centres.”

The NPC investment program is designed to inject capital into high-potential companies, while de-risking the investment of private investors. In this case, NPC’s investment was leveraged almost three-fold by a group of investors in Southeastern Ontario.

“The investment by NPC was a catalyst for our ability to secure interest and funding from angel and private investors,” said Rui Resendes, FireRein’s CEO. “NPC’s endorsement, coupled with input and advice on the business strategy, was a tremendous asset in helping us raise sufficient capital to scale up production and increase sales.”

Connecting key expertise and resources is central to NPC’s strategy to help Canadian companies commercialize their natural products and technologies faster, cheaper, and more efficiently.

“Canada’s natural product sector is poised to benefit from the growing global demand for healthy and sustainable products,” says NPC Board Chair, Robert Orr. “NPC’s international connections, collaborative approach, and effective mix of advisory services and investment programming, are key tools to help Canadian companies compete on the world stage.”

About Natural Products Canada: NPC is a not-for-profit organization with a vision to make Canada flourish as the Silicon Valley of natural products. It aims to align, expand, and optimize the pan-Canadian natural products ecosystem to accelerate the development of products and technology platforms that bring real value to real customers. NPC was established in 2016, and is funded by a range of public and private investors, including the Government of Canada’s Centre of Excellence in Commercialization and Research (CECR) program administered by the Networks of Centres of Excellence.


Posted in Uncategorized

Emergence client, PEI Juice Works, targets commercial animal feed and nutraceutical markets

Emergence client, PEI Juice Works, is a PEI-based agri-food processing company that is having great success sharing Prince Edward Island’s abundant wild blueberries with the rest of the world. You can check out their story on the website of our program partner, Food Island Partnership.

JWLogoPEI Juice Works’ General Manager, Jackson Platts told us the company recognized the opportunity to juice in bulk with the explosion of the craft brew market along the eastern seaboard. About 75% of PEI Juice Works’ 100% blueberry juice is shipped to China, Taiwan, Japan, Barbados, the U.S. and Europe. China represents the largest single market for the company.

Blueberries, which are considered a superfruit high in antioxidants and believed to have restorative qualities, are in high demand worldwide.

Each 375 ml bottle of juice contains just over one pound of wild blueberries. The addition of rhubarb, tart cherries and cranberries has created three unique blends that complement the natural essence of the wild blueberries.

This innovative company doesn’t waste anything. They’re now using the skin of blueberries, dried and ground to a powder, for the commercial animal feed market, and the nutraceutical industry.

“You’ve got to find a way to pay the bills,” Platts jokes. “We continue to try to develop new products and new markets.”

Posted in Clients, News

Welcome to new Emergence client, Sona Nanotech Ltd.

We are happy to extend a warm “EmerGence welcome” to our newest client, Halifax, Nova Scotia-based Sona Nanotech Ltd. Welcome to Canada’s bioscience incubation program!

Sona_Logo_Light_BG[1]Sona Nanotech is a Canadian gold nanorod platform technology company.

Sona owns all of its patent-pending intellectual property for the world’s first two new gold nanorod product lines designed to support the development of dramatically improved next-generation diagnostic products and medical applications.

Sona is a privately-funded company and has received support from the Atlantic Canada Opportunities Agency and the National Research Council Industrial Research Assistance Program (IRAP) programs for product and technology development.

Sona-gemini-gold-nanorods-900nmSona’s scientific team consists of surface chemists with 50+ years of combined experience in nanotechnology, surface and colloidal chemistry. This team has developed the first line of biocompatible gold nanorods (GNRs) that are synthesized without the use of the conventionally used cytotoxic surfactant cetyltrimethylammonium bromide, commonly called CTAB.

Key features of Sona’s products include:

  • More colour options for medical imaging and diagnostic test results than traditional gold nanoSphere products.
  • 100% CTAB free – the world’s first gold nanorods engineered to be live-cell friendly.
  • Longer shelf life than competing gold nanorod or nanoSphere products.
  • Increased sensitivity for improved diagnostic applications.
  • Superior heat generating capacity that nanoSpheres for medical applications.
  • Thermal stability not offered by competing gold nanorod or nanoSphere technologies.

Sona is working with collaboration partners across Canada, the US and Europe to complete research data results and product prototyping, where their Sona Gemini™ and Omni™ brand gold nanorod products will be used as the enabling nanoparticle platform technology for projects ranging from cancer tumour destruction in humans and animals to targeted drug delivery, and new diagnostic test product platforms for infectious disease and women’s health.

Contact Sona Nanotech for further information!

Posted in Clients, News